New 300 mg Reyataz Capsule Approved
October 23, 2006
On October 16, 2006, the Food and Drug Administration approved a new 300 mg capsule form of Reyataz (atazanavir).
Reyataz is now available as 100mg, 150 mg, 200 mg, and the new 300 mg capsules.
The new 300 mg capsules give treatment-experienced patients the option to take either one 300 mg capsule, or two 150 mg capsules of Reyataz, once daily plus ritonavir 100 mg once daily, with food.
The recommended dose for treatment-naive patients remains unchanged and is Reyataz 400 mg (two 200mg capsules) once daily with food.
Reyataz is a product of Bristol-Myers Squibb.
Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.